Martin Bushell
Overview
Explore the profile of Martin Bushell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
4337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Gillen S, Giacomelli C, Hodge K, Zanivan S, Bushell M, Wilczynska A
Genome Biol
. 2021 Oct;
22(1):284.
PMID: 34615539
Background: Regulation of protein output at the level of translation allows for a rapid adaptation to dynamic changes to the cell's requirements. This precise control of gene expression is achieved...
22.
Gillen S, Waldron J, Bushell M
Oncogene
. 2021 Sep;
40(45):6309-6320.
PMID: 34584217
A key characteristic of cancer cells is their increased proliferative capacity, which requires elevated levels of protein synthesis. The process of protein synthesis involves the translation of codons within the...
23.
Grosso S, Marini A, Gyuraszova K, Vande Voorde J, Sfakianos A, Garland G, et al.
Nat Commun
. 2021 Aug;
12(1):4920.
PMID: 34389715
Malignant mesothelioma (MpM) is an aggressive, invariably fatal tumour that is causally linked with asbestos exposure. The disease primarily results from loss of tumour suppressor gene function and there are...
24.
Bader A, Bushell M
DNA Repair (Amst)
. 2021 Jun;
105:103158.
PMID: 34147942
The advent of genome-wide methods for identifying novel components in biological processes including CRISPR screens and proteomic studies, has transformed the research landscape within the biological sciences. However, each study...
25.
de Almeida-Faria J, Duque-Guimaraes D, Ong T, Pantaleao L, Carpenter A, Loche E, et al.
Diabetologia
. 2021 Jan;
64(4):890-902.
PMID: 33501603
Aims/hypothesis: Levels of the microRNA (miRNA) miR-126-3p are programmed cell-autonomously in visceral adipose tissue of adult offspring born to obese female C57BL/6J mice. The spectrum of miR-126-3p targets and thus...
26.
Najumudeen A, Ceteci F, Fey S, Hamm G, Steven R, Hall H, et al.
Nat Genet
. 2021 Jan;
53(1):16-26.
PMID: 33414552
Oncogenic KRAS mutations and inactivation of the APC tumor suppressor co-occur in colorectal cancer (CRC). Despite efforts to target mutant KRAS directly, most therapeutic approaches focus on downstream pathways, albeit...
27.
Smith E, Benbahouche N, Morris K, Wilczynska A, Gillen S, Schmidt T, et al.
Nucleic Acids Res
. 2020 Dec;
49(1):458-478.
PMID: 33332560
The mammalian target of rapamycin (mTOR) is a critical regulator of cell growth, integrating multiple signalling cues and pathways. Key among the downstream activities of mTOR is the control of...
28.
Knight J, Alexandrou C, Skalka G, Vlahov N, Pennel K, Officer L, et al.
Cancer Discov
. 2020 Dec;
11(5):1228-1247.
PMID: 33328217
-mutant colorectal cancers are resistant to therapeutics, presenting a significant problem for ∼40% of cases. Rapalogs, which inhibit mTORC1 and thus protein synthesis, are significantly less potent in -mutant colorectal...
29.
Valtonen S, Vuorinen E, Kariniemi T, Eskonen V, Le Quesne J, Bushell M, et al.
Anal Chem
. 2020 Nov;
92(24):15781-15788.
PMID: 33237744
Protein-protein interactions (PPIs) are an essential part of correct cellular functionality, making them increasingly interesting drug targets. While Förster resonance energy transfer-based methods have traditionally been widely used for PPI...
30.
In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer
Rushworth L, Harle V, Repiscak P, Clark W, Shaw R, Hall H, et al.
Life Sci Alliance
. 2020 Oct;
3(12).
PMID: 33033111
Docetaxel chemotherapy in metastatic prostate cancer offers only a modest survival benefit because of emerging resistance. To identify candidate therapeutic gene targets, we applied a murine prostate cancer orthograft model...